InMed Pharmaceuticals Reports Sales Growth Amid Rising Losses and Funding Concerns

Company Overview: InMed Pharmaceuticals Inc. (NASDAQ: INM) focuses on developing therapeutic products for serious diseases, particularly through rare cannabinoids and novel cannabinoid analogs. The company has been actively pursuing diverse projects concentrated on unmet medical needs and manufacturing technologies.

Recent Developments:

• As of March 31, 2025, InMed reported sales of $3,637,923 for the nine-month period, showing a growth from $3,314,663 in the previous year.
• Operating losses increased to $(6,373,822) for the nine months ended March 31, 2025, from $(5,737,879) during the same period in 2024.
• The company's accumulated deficit reached approximately $115.4 million.
• Cash and cash equivalents declined to $4,679,826 from $6,571,610 in December 2024.

Positive Aspects of the Income Statement:

• Sales growth of 10% YoY from BayMedica's products, indicating expansion in the commercial sector.
• Gross profit margin for the nine months significantly improved, showing operational adjustments are positively impacting sales yields.

Negative Aspects of the Income Statement:

• Net loss per share decreased to $(7.93) from $(16.48), although still reflecting substantial ongoing losses.
• Operating expenses rose mainly due to increased research and development, totaling $7,256,400 for nine months versus $6,796,982 in 2024.

Key Financial Statistics:

• Total revenues for Q1 2025: $1,261,578.
• Total operating expenses for Q1 2025: $2,313,120, compared to $2,133,782 in Q1 2024.
• Cash used in operating activities for the nine-months: $(5,988,445).
• Research and development expenses increased to $2,715,044 for the nine months, a 10% increase from prior year.

Looking Ahead: The company's future viability remains contingent on its ability to secure additional funding to ensure continued operations, alongside advancing its drug candidates into clinical trials. The overall financial projections remain cautious given the ongoing operating losses and market dynamics affecting capital raises.